London: Lung cancer sufferers, who have stopped responding to chemotherapy, could benefit from a new drug which is undergoing tests.
The experimental drug, known as LY2181308, aims to stop the growth of deadly tumours by blocking a protein that allows them to develop.
If the trial - being carried out at Oxford Radcliffe Hospitals with teams from Oxford University and Cancer Research UK - is successful it could lead to new treatment for patients with advanced lung cancer and give them longer to live.
The disease, which is contracted by 30,000 people a year in Britain alone, often goes undiagnosed until it has become advanced and currently fewer than 10 percent of sufferers survive for five years after diagnosis, the Telegraph reports.
Denis Talbot at The University of Oxford, said: "It`s greatly encouraging that we`re able to take this new experimental drug to treat lung cancer into further development. We hope that it may increase survival rates for lung cancer patients."
Lung cancer sufferers are usually given a drug called docetaxel if their disease continues to develop after they have the standard chemotherapy treatment. The experimental drug will undergo an international trial soon.